AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03087565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subtotal hystrectomy
Description: A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing.
Study NCT03087565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hystrectomy
Description: A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.~The abdomen is closed in layers; the wound is covered with a sterile dressing.
Study NCT04044456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments.
Study NCT04044456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training
Description: Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises.
Study NCT04044456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brain Health Workshop
Description: . BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
Study NCT04044456 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: National geographic movies
Description: participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
Study NCT02311530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Description: Extended Release Tablets, 10mg
Study NCT02311530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine (Plendil®)
Study NCT03235505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
Study NCT03235505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline Tartrate
Description: Varenicline + Innokin Endura T20S electronic inhaler but without any nicotine content + MI
Study NCT03235505 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Interview
Description: Placebo-varenicline + Innokin ENdura T20S electronic inhaler but without any nicotine content +MI
Study NCT02241122 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prostate biopsy
Study NCT02545777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium enteric-coated
Study NCT02545777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral medicine of tonifying spleen and descending turbid
Description: Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
Study NCT02545777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steeping and washing medicine of descending turbid and clearing heat
Description: Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
Study NCT02545777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wet wrapping medicine of descending turbid and clearing heat
Description: Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
Study NCT02450266 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic transrectal ultrasound-guided prostate biopsy
Description: 12-18 systematic biopsy cores
Study NCT02450266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI/ultrasound fusion-guided prostate biopsy
Description: 2 targeted biopsy cores from each prostate lesion
Study NCT02047500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TH-302
Description: TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT02047500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT02047500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose ranging from 800-1000 mg/m\^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
Study NCT03388567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staff pharmacy whith intervention
Description: Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
Study NCT01136226 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eligard (TM)
Description: Eligard (TM) 22.5 mg administered at baseline and Month 3
Study NCT00614159 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Weight based dosage for Peds subjects, used for duration of the endoscopy.
Study NCT00614159 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Weight based dosage for Peds subjects, used for duration of the endoscopy.
Study NCT00580853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
Study NCT00580853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: 300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
Study NCT00580853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04555525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sarecycline
Description: sarecycline tablet
Study NCT04555525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Centrum Adult Multivitamin
Description: Centrum Adult Mulltivitamin tablet
Study NCT02791776 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scoliosis
Description: self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters
Study NCT03743428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate Tablets
Description: Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
Study NCT03743428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
Study NCT03286374 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Occupational rehabilitation
Description: The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~1. Four weeks with an institutional stay at Muritunet (BL)~2. Follow-up;~   1. Eight weeks, telephone contact between therapist at Muritunet and the participant.~  2. 16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~  3. 28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~  4. 40 weeks, telephone contact between therapist at Muritunet and the participant.~  5. 52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)
Study NCT01845740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milatuzumab
Description: Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
Study NCT05624021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular functional training
Description: The scapular functional training consists of press up and push up plus. Press up was done in sitting position on the training bench, feet on the floor with straight arm and the palms on the edge of the bench fingers pointing forward and then lift off and dip down just in front of the seat by moving the shoulder girdle. Progression is done by placing weight on the thigh. Push-up plus exercise started from a push up position on the hand, feet or knees and keeping the torso rigid by bracing the abdominals followed by protracting the scapula as high as possible. Progression is done moving from knees to the feet or adding resistance on the upper back. The training continued for three sessions per week for four weeks.
Study NCT05624021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical isometric exercises
Description: The isometric neck exercises taught to all the participants to perform in neutral sitting positions at home thrice a day for 15-days continuously. The sequences of exercises were shoulder circling in clockwise and anticlockwise direction, scapular retraction with cervical retraction, neck flexion, extension, either side of lateral bending/flexion, left and right rotation. Each exercise follows a set of 10 repetition of maximum voluntary contraction with a progressive hold time of 3, 5, 7, and 10 seconds depending on the severity of pain and tolerance of the participants.
Study NCT05624021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical isometric exercises
Description: The isometric neck exercises taught to all the participants to perform in neutral sitting positions at home thrice a day for 15-days continuously. The sequences of exercises were shoulder circling in clockwise and anticlockwise direction, scapular retraction with cervical retraction, neck flexion, extension, either side of lateral bending/flexion, left and right rotation. Each exercise follows a set of 10 repetition of maximum voluntary contraction with a progressive hold time of 3, 5, 7, and 10 seconds depending on the severity of pain and tolerance of the participants.
Study NCT05624021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moist heating
Description: A hydrocollator moist heat packs was applied over back of the neck in supine position to receive optimal heating. It was given for 20 minutes/day, five-day a week for four-week.
Study NCT01845740 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously once weekly for 4 weeks.
Study NCT03985891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Monoclonal Antibody JS001
Description: Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
Study NCT03985891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Folfox
Study NCT03985891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Folfox
Study NCT01032733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
Study NCT01032733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Control
Description: Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
Study NCT00626925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
Study NCT00003006 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00003006 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study NCT04995185 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (18)F-fluoromisonidazole (FMISO)
Description: Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.
Study NCT04150003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation program
Description: Structured rehabilitation program of directed exercises
Study NCT04150003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care for patients who had suffered a Pulmonary Embolism
Study NCT03475082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (>50Hz), low frequency (\<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
Study NCT03475082 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (>50Hz), low frequency (\<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
Study NCT02703350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)
Study NCT02703350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT03483987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sof+Ledi+R arm
Description: Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
Study NCT03483987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sof+Ledi+R+Peg-IFN arm
Description: Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
Study NCT03483987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sof+Dacla+R arm
Description: Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
Study NCT03483987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sof+Dacla+R+Peg-IFN arm
Description: Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
Study NCT03483987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sof+Velpa+R arm
Description: Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
Study NCT03483987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sof+Velpa+R+Peg-IFN arm
Description: Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight \<75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
Study NCT03956472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic protocol for improving drainage of LCS
Description: Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
Study NCT03956472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP 10cmH2O
Description: Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
Study NCT03956472 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fake Osteopathic protocol
Description: Placebo intervention
Study NCT03956472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fake Osteopathic protocol
Description: Placebo intervention
Study NCT03956472 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PEEP-Sham
Description: PEEP 0 cmH2O (hidden)
Study NCT03956472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP-Sham
Description: PEEP 0 cmH2O (hidden)
Study NCT00835848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
Study NCT00835848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
Study NCT02436330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: 6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc.
Study NCT02436330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic health teaching
Description: 6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
Study NCT02436330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic health teaching
Description: 6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.